Arrowstreet Capital, Limited Partnership Biogen Inc. Transaction History

Arrowstreet Capital, Limited Partnership

$136 Billion
Q2 2025

A detailed history of Arrowstreet Capital, Limited Partnership transactions in Biogen Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 624,371 shares of BIIB stock, worth $80.5 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

624,371

Previous 214,780 190.7%

Holding current value

$80.5 Million

Previous $29.4 Million 166.81%

% of portfolio

0.06%

Previous 0.02%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$113.38 - $135.49 $46.4 Million - $55.5 Million	409,591 Added 190.7%	624,371 $78.4 Million
Q1 2025 May 14, 2025	BUY	$133.43 - $153.27 $28.7 Million - $32.9 Million	214,780 New	214,780 $29.4 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $25 Million - $28.3 Million	-98,889 Reduced 33.43%	196,954 $50.6 Million
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $1.4 Million - $1.62 Million	5,103 Added 1.76%	295,843 $84.3 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $40 Million - $45.6 Million	-156,059 Reduced 34.93%	290,740 $80.8 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $46.4 Million - $56.3 Million	-183,697 Reduced 29.14%	446,799 $124 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $7.86 Million - $10.8 Million	40,394 Added 6.85%	630,496 $168 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $74.6 Million - $88.8 Million	-397,975 Reduced 40.28%	590,102 $120 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $4.3 Million - $5.42 Million	22,215 Added 2.3%	988,077 $208 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $155 Million - $199 Million	691,743 Added 252.35%	965,862 $232 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $24.7 Million - $32.2 Million	87,302 Added 46.73%	274,119 $77.6 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $48.4 Million - $77.5 Million	186,817 New	186,817 $64.7 Million
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $76.9 Million - $90.1 Million	-316,606 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$236.26 - $355.63 $4.32 Million - $6.51 Million	18,301 Added 6.13%	316,606 $77.5 Million
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $109 Million - $126 Million	-412,294 Reduced 58.02%	298,305 $84.6 Million
Q2 2020 Aug 12, 2020	SELL	$258.66 - $342.55 $190 Million - $252 Million	-735,860 Reduced 50.87%	710,599 $190 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $262 Million - $332 Million	-973,732 Reduced 40.23%	1,446,459 $458 Million
Q4 2019 Feb 13, 2020	SELL	$220.06 - $304.07 $53.3 Million - $73.6 Million	-242,164 Reduced 9.1%	2,420,191 $718 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $36.4 Million - $40.9 Million	167,598 Added 6.72%	2,662,355 $620 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $171 Million - $188 Million	778,167 Added 45.33%	2,494,757 $583 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $41.7 Million - $65.3 Million	192,501 Added 12.63%	1,716,590 $406 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $26.2 Million - $33.2 Million	94,227 Added 6.59%	1,524,089 $459 Million
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $111 Million - $145 Million	-376,925 Reduced 20.86%	1,429,862 $505 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $171 Million - $203 Million	662,933 Added 57.96%	1,806,787 $524 Million
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $285 Million - $403 Million	1,094,854 Added 2234.4%	1,143,854 $313 Million
Q4 2017 Feb 09, 2018	BUY	$307.64 - $344.58 $15.1 Million - $16.9 Million	49,000	49,000 $15.6 Million

Others Institutions Holding BIIB

# of Institutions

1,015

Shares Held

131M

Call Options Held

2.73M

Put Options Held

2.47M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $18.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Account

Arrowstreet Capital, Limited Partnership Biogen Inc. Transaction History